GleamWall
中文EN

FLNA FILANA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.87M$3.30M$4.54M$3.85M$3.96M$5.12M$13.67M$20.53M
SG&A expense$7.41M$6.09M$6.62M$9.70M$7.91M$40.28M$10.92M$8.96M
Operating income-$11.27M-$9.39M-$11.17M-$13.55M-$11.86M-$45.39M-$24.59M-$29.49M
Income tax$0$0$0$0$0$0$0$0
Net income-$10.73M-$8.60M-$10.33M-$12.54M-$10.81M-$44.22M-$23.40M-$27.60M
EBITDA-$11.07M-$9.09M-$10.93M-$13.22M-$11.66M-$45.19M-$24.37M-$29.26M
EPS (basic)-0.22-0.18-0.21—-0.22-0.92-0.48—
EPS (diluted)————-0.22-0.92-0.48—
Weighted avg. shares (diluted)————48.31M48.31M48.26M—
Balance sheet
Cash & equivalents$46.99M$82.68M$86.57M$95.50M$106.08M$112.38M$117.33M$128.57M
Current assets$80.06M$83.72M$87.96M$97.71M$108.91M$114.82M$120.15M$136.53M
PP&E, net$20.00M$20.18M$20.40M$20.65M$20.82M$20.56M$20.78M$21.00M
Intangibles———$193,000———$37,000
Total assets$100.06M$103.90M$108.37M$118.36M$129.73M$135.38M$140.93M$157.53M
Current liabilities$41.95M$40.16M$40.12M$43.83M$48.05M$47.33M$13.24M$11.75M
Total liabilities$42.08M$40.29M$40.23M$43.95M$48.16M$47.41M$13.32M$11.83M
Shareholders' equity$57.98M$63.61M$68.14M$74.40M$81.57M$87.97M$127.62M$145.70M
Shares outstanding50.07M48.31M48.31M48.31M48.31M48.31M48.31M48.20M
Cash flow statement
Operating cash flow-$6.09M-$3.85M-$8.88M-$9.75M-$6.22M-$4.95M-$11.34M-$61.27M
Capital expenditure$31,000——$501,000$80,000$0$0$57,000
Free cash flow-$6.12M——-$10.25M-$6.30M-$4.95M-$11.34M-$61.32M
Investing cash flow-$31,000——-$501,000-$80,000$0$0-$57,000
Financing cash flow$1.68M-$16,000-$51,000-$329,000$0$0$90,000$918,000
Depreciation & amortization$200,000$300,000$243,000$334,000$200,000$200,000$220,000$228,000
Stock-based compensation$3.48M$4.07M$4.07M$5.37M$4.40M$4.58M$5.22M$5.74M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.